Publications

121 Publications

 

2021

PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue. Rahman SA, Yagnik B, Bally AP, Morrow KN, Wang S, Vanderford TH, Freeman GJ, Ahmed R, Amara RR. Sci Immunol. 2021 Sep 10

A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs. Routhu NK, Cheedarla N, Gangadhara S, Bollimpelli VS, Boddapati AK, Shiferaw A, Rahman SA, Sahoo A, Edara VV, Lai L, Floyd K, Wang S, Fischinger S, Atyeo C, Shin SA, Gumber S, Kirejczyk S, Cohen J, Jean SM, Wood JS, Connor-Stroud F, Stammen RL, Upadhyay AA, Pellegrini K, Montefiori D, Shi PY, Menachery VD, Alter G, Vanderford TH, Bosinger SE, Suthar MS, Amara RR. Immunity. 2021 Mar 9

SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Routhu NK, Cheedarla N, Bollimpelli VS, Gangadhara S, Edara VV, Lai L, Sahoo A, Shiferaw A, Styles TM, Floyd K, Fischinger S, Atyeo C, Shin SA, Gumber S, Kirejczyk S, Dinnon KH 3rd, Shi PY, Menachery VD, Tomai M, Fox CB, Alter G, Vanderford TH, Gralinski L, Suthar MS, Amara RR.  Nat Commun. 2021 Jun 11

Improving rigor and reproducibility in nonhuman primate research. Bliss-Moreau E, Amara RR, Buffalo EA, Colman RJ, Embers ME, Morrison JH, Quillen EE, Sacha JB, Roberts CT; National Primate Research Center Consortium Rigor and Reproducibility Working Group. Am J Primatol. 2021 Sep 20

Circulating integrin α4 β7 + CD4 T cells are enriched for proliferative transcriptional programs in HIV infection. Lakshmanappa YS, Roh JW, Rane NN, Dinasarapu AR, Tran DD, Velu V, Sheth AN, Ofotokun I, Amara RR, Kelley CF, Waetjen E, Iyer SS. FEBS Lett. 2021 Sep

Oral Vaccination Approaches for Anti-SHIV Immunity. Velarde de la Cruz E, Wang L, Bose D, Gangadhara S, Wilson RL, Amara RR, Kozlowski PA, Aldovini A. FrontImmunol. 2021 Jun 21

The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. Charles TP, Burton SL, Arunachalam PS, Cottrell CA, Sewall LM, Bollimpelli VS, Gangadhara S, Dey AK, Ward AB, Shaw GM, Hunter E, Amara RR, Pulendran B, van Gils MJ, Derdeyn CA. PLoS Pathog. 2021 Feb 8

Clinical and whole genome characterization of SARS-CoV-2 in India. Muttineni R, Kammili N, Bingi TC, Rao M R, Putty K, Dholaniya PS, Puli RK, Pakalapati S, S S, K S, Doodipala MR, Upadhyay AA, Bosinger SE, Amara RR, Kondapi AK. PLoS One. 2021 Feb 2

Cutting Edge: Mouse SARS-CoV-2 Epitope Reveals Infection and Vaccine-Elicited CD8 T Cell Responses. Joag V, Wijeyesinghe S, Stolley JM, Quarnstrom CF, Dileepan T, Soerens AG, Sangala JA, O'Flanagan SD, Gavil NV, Hong SW, Bhela S, Gangadhara S, Weyu E, Matchett WE, Thiede J, Krishna V, Cheeran MC, Bold TD, Amara R, Southern P, Hart GT, Schifanella L, Vezys V, Jenkins MK, Langlois RA, Masopust D. J Immunol. 2021 Mar 1

Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses. Berendam SJ, Styles TM, Morgan-Asiedu PK, Tenney D, Kumar A, Obregon-Perko V, Bar KJ, Saunders KO, Santra S, De Paris K, Tomaras GD, Chahroudi A, Permar SR, Amara RR, Fouda GG. J Virol. 2021 Jan 13

Older